Slower Worsening Is Still Worsening
Read the transcript of “Slower Worsening Is Still Worsening”
Film transcript: Slower Worsening Is Still Worsening
A drug clears amyloid from the brain. Does that help the person whose brain it is? The antibody lecanemab clears amyloid plaques. In a large trial, people with early Alzheimer disease got it or a placebo. Both groups were followed for a year and a half. The outcome was a clinician's rating of thinking and daily function. It runs from zero to eighteen, and higher means worse. The graph shows each group's change from its starting score. Here is a question. Did the treated group get better?
No. Both lines rise. Both groups got worse. The treated group got worse more slowly. To compare them, take the gap as a share of the placebo group's decline. The gap is a little more than a quarter of the placebo decline. That share is called the relative slowing. That share compares two amounts of decline. It is not a gain in memory. It is not the share of patients helped. It is not anyone's prognosis.
Slower worsening is still worsening. In this trial, a drug that clears amyloid slowed the disease. It did not stop it. A second trial tested a different antibody, solanezumab. It enrolled older adults whose thinking was still normal, but whose brains held extra amyloid. On PET scans, amyloid rose in both groups. It rose more slowly with the drug. Predict. Did their thinking decline more slowly too?
Both groups declined. The trial did not demonstrate slower decline with the drug, despite the smaller rise in amyloid. ALS shows the same thing. In people with S .O .D .1, a L .S., a drug called tofersen lowered SOD1. It also lowered a blood marker of axon damage. But over twenty-eight weeks, the clinical measures did not improve. That is the treatment question. A marker can guide you. But a clinical outcome is what tells you whether changing the target helps. Benefits also have costs. Another antibody, donanemab, was tested in a large trial. Brain swelling or fluid on MRI was far more common with it than on placebo.
Read a trial as two amounts of decline. And keep a change in a marker apart from a change in the person.
Lecanemab slowed worsening in early Alzheimer disease by about 27%. The treated group still got worse.
Continue in the lesson: When Mature Neurons Fail: Neurodegeneration →
2:57 · Free, with captions and a transcript. The lesson has the full text, the questions and the sources.
More films from this lesson
How this film was made. Narration: an AI narrator voice (Kokoro, af_heart) reading narration written from this lesson's text. Animation: AI-generated in code (Manim) by Claude, a schematic with no drawn molecular structures. Captions come from the narration script. See something wrong? Report it.